Welcome to Solvotrin Innovations
Solvotrin Innovations Limited is a privately held pharmaceutical company with a portfolio of innovative products for the treatment of rare diseases, cardiovascular disease and cancer. Solvotrin Innovationsí intellectual property protects a family of nitric oxide releasing tetracycline drugs called nitrocyclines with significant clinical advantages over currently available drugs.
Nitrocyclines modulate many inflammatory chemicals including Matrix Metalloproteinase type-9 (“MMP-9”). Lead nitrocyclines, SI1004 and SI1005 are more effective than conventional tetracyclines in reducing MMP-9 and inflammatory chemicals.
Their promise is clearly defined in a rare disease called Marfan syndrome. MMP enzymes, especially MMP-9, and inflammation are long known to be involved in the development and progression of cancer. They are also involved in cardiovascular diseases leading to heart failure, hypertension (high blood pressure) and myocardial infarction (heart attack). These diseases affect more than 100 million people in the USA and EU.
Headquartered in Cork, Ireland, Solvotrin Innovations also has offices and laboratories in Dublin.